Cargando…
Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
Bispecific antibodies are emerging as a promising new immunotherapy modality and are actively being evaluated in clinical trials for patients with lymphoma. As the first BsAb to receive regulatory approval for lymphoma, mosunetuzumab, an antiCD20/anti-CD3 BsAb, is an exciting new option for patients...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308681/ https://www.ncbi.nlm.nih.gov/pubmed/37381053 http://dx.doi.org/10.1186/s13045-023-01462-0 |